BOLD                                            melanoma(102,103)
 _________________________________________________________________
  bleomycin....... 7.5 U (first course); 15 U (subsequent courses) 
                   SC on days 1 and 4.
  vincristine..... 1 mg/sqm (maximum single dose 2.5 mg) IV on 
                   days 1 and 5.
  lomustine....... 80 mg/sqm (maximum single dose 150 mg) orally 
                   on day 1.
  dacarbazine..... 200 mg/sqm/day (maximum single dose 400 mg) IV 
                   from day 1 to day 5.
  FREQUENCY....... Repeat cycles every 4 to 6 weeks.

  reference...
    Seigler HF.  Lucas VS Jr.  Pickett NJ.  Huang AT. DTIC, CCNU, 
    bleomycin and vincristine (BOLD) in metastatic melanoma. 
    Cancer.  46(11):2346-8, 1980 Dec 1. 
  abstract...
    Treatment of 91 consecutive patients having metastatic, Stage 
    IV melanoma who had not received any previous chemotherapy was 
    begun between January 1977 and April 1978. The therapy 
    included bleomycin (B) at 7.5 units subcutaneously in the 
    first course and 15 units in subsequent courses on days 1 and 
    4; vincristine or Oncovin (O) at 1 mg/m2 intravenously on days 
    1 and 5; CCNU or lomustine (L) at 80 mg/m2 p.o. on day 1 and 
    DTIC (D) 200 mg/m2 intravenously on days 1 through 5. 
    Evaluable patients (72) were those who had measurable tumours 
    in the viscera and on the skin. Seven patients (9%) responded 
    with complete tumor regression (CR), 22 (31%) with partial 
    regression (PR) (50% or more tumor regression), 12 (17%) with 
    stabilization of disease, and 31 (43%) with progression of the 
    disease. Patients who responded with CR, PR, and stable 
    disease (41 patients) had a median survival of 67 weeks, while 
    those who did not respond (31 patients) had a median survival 
    of 20 weeks (P < .0001). Overall median survival was 31 weeks. 
    The bleomycin-Oncovin-lomustine-DTIC (BOLD) regimen is an 
    effective alternative treatment for metastatic melanoma; there 
    is good tumor response and prolongation of survival in the 
    responding patients. Its overall toxicity is mild to moderate. 

  103. Ahn SS, Morton DL. Preliminary results of BOLD for 
       disseminated melanoma. Proc Am Soc Clin Oncol 1:179, 1982.